



401 WEST MAIN ST., SUITE 222 · LEXINGTON, KY 40507 · 859-759-4081 · CONTACTUS@RMTCNET.COM · RMTCNET.COM

MEMORANDUM

TO: Association of Racing Commissioners International

FROM: RMTC Board of Directors

DATE: October 28, 2023

RE: *Proposed Classification*

The RMTC is submitting a recommendation for a penalty classification for Cabergoline.

Cabergoline

Cabergoline is FDA approved for use in humans. It is an ergot-derived long-acting dopamine D2 receptor agonist used to treat pituitary tumors, Parkinson's Disease, and suppress secretion of prolactin and secondarily increase testosterone concentrations. Additionally, there is literature supporting its use as a medical management for treating pyometras in small animals due to its anti-prolactin effects.

Cabergoline is not FDA approved for use in animals and is not considered a therapeutic agent for use in horses.

It is not listed in the ARCI's Uniform Classification of Foreign Substances, so pursuant to ARCI Model Rules, it is assigned 1A by default.

Bromocriptine (same class of medication) is listed in ARCI's document as a 2A, Pergolide (FDA approved and considered a therapeutic agent in horses) is listed as a 3B. It is reasonable to accept a 2A classification for Cabergoline as the recommended designation from the RMTC.

Based on intelligence received regarding confiscation of contraband labeled with this substance and potential emerging threat, RMTC's Board of Directors voted unanimously, October 2, 2023, to recommend a 2/A Classification.

Recommendation: 2A